Articles on heart disease, prevention, and cardiac imaging by Dr Reza Moazzeni, MD FRACP, cardiologist in Sydney.
Clinical Guideline Summary 2026 ACC/AHA Dyslipidemia Guideline: Key Updates & LDL-C Goals A practical clinician summary of the 2026 ACC/AHA cholesterol and dyslipidemia guideline, covering PREVENT-ASCVD risk assessment, LDL-C and
Preventive Cardiology How to Lower Triglycerides Naturally Triglycerides are one of the most lifestyle-responsive numbers on your blood test. The right changes to diet, alcohol, weight and activity can lower
Heartcare Sydney · Patient Guide Stress Echocardiogram Explained: Preparation, Procedure and Results Dr Reza Moazzeni · Consultant Cardiologist (FRACP) A guide to stress echocardiography — why the test is requested,
HEARTCARE SYDNEY · PATIENT RESOURCES Echocardiogram Explained: What It Shows and What to Expect A cardiologist’s guide to the heart ultrasound — what it can and cannot show, the main
Lipoprotein(a) [Lp(a)]: comprehensive review and 2026 update Lipoprotein(a), or Lp(a), is a genetically determined LDL-like particle that increases the risk of atherosclerotic cardiovascular disease and calcific aortic valve stenosis. Because
Alcohol affects the heart in more ways than most people realise — it can raise blood pressure, trigger atrial fibrillation, increase stroke risk, disturb sleep, drive weight gain, push up
Lipoedema is a chronic, often painful disorder of fat distribution that overwhelmingly affects women and is commonly mistaken for ordinary weight gain. The fat is disproportionate, symmetrical, tender, bruises easily,
Hypercholesterolemia or high blood cholesterol level is common in medical practice, but not all cases are equal. Some individuals may have a transient spike in cholesterol due to dietary indiscretions
Preventive Cardiology Inclisiran (Leqvio): Twice-Yearly LDL Cholesterol Injection How inclisiran silences PCSK9 production in the liver to lower LDL cholesterol by about 50% — the RNA-interference mechanism, the latest ORION
Preventive Cardiology PCSK9 Inhibitors: Evolocumab and Inclisiran How PCSK9 inhibitors lower LDL cholesterol by about 50–60% — the mechanism, trial evidence, safety, and access in Australia. Dr Reza Moazzeni, MD
